ERBB2 and neoplasm: The data on the efficacy of T-DXd in HER2-overexpressing NSCLC and MBC suggest that while T-DXd has anti-tumor activity in HER2-overexpressing NSCLC, its efficacy is limited compared to that in HER2-positive MBC.